GeoVax's Next-Generation COVID-19 Vaccine Shows Promise for Immunocompromised Patients in European Society of Medicine Publication

The European Society of Medicine's journal Medical Research Archives has published a peer-reviewed article detailing GeoVax Labs' next-generation COVID-19 vaccine candidate, GEO-CM04S1, which is specifically designed for immunocompromised patients who often respond inadequately to currently authorized vaccines. The article, titled "GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients," provides a comprehensive review of the vaccine's scientific rationale, preclinical studies, and clinical findings supporting its development for this vulnerable population.

GEO-CM04S1's dual-antigen design incorporates both the spike (S) and nucleocapsid (N) proteins of SARS-CoV-2 delivered via a Modified Vaccinia Ankara (MVA) viral vector platform. This approach aims to generate both antibody and T-cell responses that are broad and durable, addressing limitations of single-antigen vaccines that primarily target the spike protein. The publication highlights how next-generation vaccines designed to stimulate more robust and durable cellular immunity may offer improved protection for high-risk populations.

Key scientific findings from the publication include the vaccine's ability to stimulate immune responses against conserved viral targets less susceptible to mutation and immune escape. Preclinical and clinical data show GEO-CM04S1 induces strong CD4+ and CD8+ T-cell responses critical for controlling viral infection and reducing progression to severe disease. Early clinical studies demonstrated a benign safety profile and strong immunologic responses, including seroconversion and cellular immune activation across multiple dose levels.

Encouraging results from ongoing Phase 2 clinical trials in immunocompromised patients, including those with hematologic malignancies receiving cell transplants and individuals with chronic lymphocytic leukemia, indicate the vaccine can generate durable immune responses even in patients with impaired immune systems. David Dodd, Chairman and Chief Executive Officer of GeoVax, emphasized the significance of this development, stating that an estimated 40+ million patients in the U.S. are considered immunocompromised, including patients with cancer, transplant recipients, individuals receiving immunosuppressive therapies, and those with chronic diseases. Worldwide, approximately 400 million patients have weakened immune systems, rendering them at higher risk of severe COVID-19 outcomes.

Mark J. Newman, PhD, Chief Scientific Officer of GeoVax and co-author of the publication, explained that GEO-CM04S1 was designed specifically to stimulate T-cell responses that may be particularly important for immunocompromised individuals who often fail to generate adequate antibody responses to existing vaccines. The MVA vector platform provides an ideal backbone for next-generation vaccines due to its ability to safely induce durable humoral and cellular immunity. The dual-antigen strategy expands immune recognition beyond the spike protein, with data from small animal studies indicating efficacy against variants is induced, potentially reducing the need to continually update vaccines.

The vaccine is currently being evaluated in multiple Phase 2 clinical trials, including primary vaccination in immunocompromised individuals and booster vaccination in patients with chronic lymphocytic leukemia. The multi-antigen design and viral vector platform are intended to provide broader, more durable immune protection and improved efficacy in populations where first-generation vaccines have demonstrated reduced effectiveness. For more information about GeoVax's broader pipeline and development programs, visit https://www.geovax.com.